Pfizer Inc.Media Contact:Victoria Davis(484) 865.5194(o)(347) 558.3455(m)orInvestor Contact:Jennifer Davis(212) 733.0717(o)(612) 940.3859(m)
Pfizer Inc. (NYSE:PFE) today announced top-line data assessing immunogenicity, tolerability and safety of Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]) in adults 18 to 49 years of age. These data support a recent
“The clinical program for Prevenar 13 demonstrates our commitment to developing vaccines that can prevent serious disease through every stage of life,” said William Gruber, M.D., senior vice president, Vaccine Clinical Research and Development, Pfizer Inc. “Prevenar 13 is the first and only pneumococcal conjugate vaccine for adults, and we continue to study the vaccine in new populations with the aim of broadening its availability.”
Pneumococcal disease is associated with significant mortality and morbidity for individuals of all ages. Prevenar 13 provides the broadest coverage of any pneumococcal conjugate vaccine and has proven effectiveness against invasive pneumococcal disease in children less than 2 years of age when used as part of a routine pediatric immunization program.
Prevenar 13 is currently approved in more than 110 countries worldwide for use in infants and young children and in more than 70 countries for use in adults 50 years of age and older. Prevenar 13 also is available through the World Health Organization (WHO) pre-qualification program for active immunization of infants and young children, as well as adults 50 years and older.
Study 6115A1-004 is a pivotal, Phase 3, multi-center trial designed to compare the immunogenicity, tolerability and safety of Prevenar 13 and the currently licensed nonconjugated pneumococcal polysaccharide vaccine (PPSV) in 740 adults 60 to 64 years of age who were naïve to PPSV, using a randomized, modified double-blind design. The study also assessed immunogenicity, tolerability and safety of Prevenar 13 administered open-label to 370 adults 50 to 59 years of age and compared to adults 60 to 64 years of age. Additionally, 900 healthy adults 18 to 49 years of age (patients with stable chronic risk conditions were eligible for inclusion) were assessed. These participants received open-label Prevenar 13 to assess the immune response to Prevenar 13 in that younger age group and to compare immune responses with participants 60 to 64 years of age. Serotype specific anti-pneumococcal functional antibodies were measured for all 18 to 49 year old participants prior to vaccination, at one month following vaccination and again at one year following vaccination with Prevenar 13.
A detailed analysis of this immunogenicity and safety study data will be submitted for future publication. Data concerning the 50 years of age and older cohorts were previously presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases in 2011.
Prevenar 13 uses Company-pioneered conjugate technology that links pneumococcal polysaccharide sugar chains found on the surface of each bacterial serotype with a carrier protein. Prevenar 13 uses the carrier protein CRM, which has more than 20 years of clinical and commercial use in vaccines.
Pneumococcal disease (PD) is a group of illnesses caused by the bacterium (, also known as pneumococcus. It can affect people of all ages, although older adults, young children and individuals with certain chronic medical conditions are at heightened risk. PD is associated with significant morbidity and mortality. Non-invasive PD includes non-bacteremic pneumococcal pneumonia (acute lower respiratory infection that affects the lungs), which is the most common form of PD in adults, as well as sinusitis (upper respiratory tract infection) and acute otitis media (middle ear infection, most often found in children). Invasive manifestations of the disease include bacteremic pneumonia (lung infection with bacteria in the blood), bacteremia (bacteria in the blood) and meningitis (infection of the tissues surrounding the brain and spinal cord).
In the European Union, Prevenar 13 is indicated for active immunization for the prevention of invasive pneumococcal disease caused by in adults aged 50 years and older caused by 13 serotypes. The vaccine is also indicated for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by in infants and children from 6 weeks to 5 years of age.
For a global summary of Prevenar 13 characteristics (SmPC), please click here
For the full prescribing information for Prevnar 13, please click here
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at .
*Prevenar 13 is referred to as Prevnar 13 in the United States.